Industries
Metabolic Disorders Therapeutics
Metabolic disorder companies develop drugs for type 2 diabetes, obesity, NASH, and dyslipidemia, with GLP-1 receptor agonists currently driving record revenues. Academic metabolic research groups at medical schools provide the mechanistic insights, mouse models, and biomarker pipelines that fuel the next generation of metabolic targets.
Details
- Companies
- Novo NordiskEli Lilly DiabetesZealand PharmaProtagonist TherapeuticsCoherus BioSciencesCarmot TherapeuticsRegeneron MetabolicsStructure TherapeuticsAltimmunePraxis BioTech
- Market Size
- $105B
- Target Researchers
- Metabolic biologists, endocrinologists, and pharmacologists specializing in GLP-1 biology, insulin signaling, adipose tissue metabolism, gut hormone interactions, NASH pathophysiology, and metabolic syndrome animal models
- Use Cases
- GLP-1 receptor agonist co-developmentNASH biomarker partnershipsAdipose biology target licensingDiabetes animal model accessMetabolomics profiling servicesGut hormone peptide chemistry consulting